ReviewFrontiers in endocrinology2023

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.

Hiroki Akiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.